Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Head and Neck Cancer: early-phase trial registry
2 of 6 indexed Metastatic Head and Neck Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Metastatic Head and Neck Cancer: 6 US clinical trials tracked, 2 recruiting.
Metastatic Head and Neck Cancer is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is PDS Biotechnology, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-head-and-neck-cancer
OPEN 2 | RECR 33% | LATE 1 | EARLY 5 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Metastatic Head and Neck Cancer lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Head and Neck Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Head and Neck Cancer is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Head and Neck Cancer research.
PDS Biotechnology accounts for 2 of 6 trials (33.3%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Head and Neck Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 95 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Metastatic Head and Neck Cancer research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
BioNTech SE
NCT04534205
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Glenn J. Hanna
NCT06239220
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PDS Biotechnology
NCT06790966
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
NCT05980000
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
PDS Biotechnology
NCT04260126
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Glenn J. Hanna
NCT05057247
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Head and Neck Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Head and Neck Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Head and Neck Cancer page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Metastatic Head and Neck Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- PDS Biotechnology sponsors the most Metastatic Head and Neck Cancer trials on record, review their full trial history before evaluating a specific study. See PDS Biotechnology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Head and Neck Cancer condition card totals 6 registered trials; most-linked intervention Pembrolizumab (KEYTRUDA®) and PDS0101; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.